T32 training program in Molecular and Systems Toxicology
T32 training program in Molecular and Systems Toxicology (NIEHS T32 ES029074) is a multi-disciplinary research mentorship program centered on training in systems toxicology including genomics/epigenetics, proteomics, and metabolomics as well as molecular approaches to investigate underlying mechanisms of toxicity. This MST training program will be supported by 16 faculty members, from the University of Colorado’s Schools of Pharmacy, Medicine and Public Health and also includes faculty from the nearby National Jewish Health, all of whom conduct systems toxicology research and will serve as mentors. Systems toxicology approaches commonly utilized by our training faculty include genomics/epigenetics, proteomics, redox proteomics, microbiome, metabolomics, biostatistical genetics, and bioinformatics.
This multi-disciplinary research T32 program will support four predoctoral trainees per year and emphasizes systems toxicology research. Graduate students in the program obtain degrees through the mentioned disciplines. Research opportunities for predoctoral trainees will involve systems-based approaches to investigate a broad range of toxicological outcomes, including environmental lung disease, carcinogenesis, neurodegenerative disease, nanotoxicology, and immune responses to environmental xenobiotics, drugs and therapies. Students will be recruited from the Toxicology and Pharmaceutical Sciences Graduate Programs, and accepted each year, into the MST-T32 program. T32 trainees are supported for 2 years, post-comps. This University of Colorado Anschutz Medical Campus MST T32 training program will develop predoctoral trainees into independent and successful toxicologists with expertise in systems toxicology.
Applications will be solicited in May of each year. Applicants must have successfully passed their comprehensive exam and currently working on research related to molecular and systems toxicology. Students from the Toxicology and Pharmaceutical Sciences PhD programs are eligible.
Emily Mitchem
Emily Mitchem is a PhD candidate in the Toxicology program at University of Colorado, Anschutz Medical Campus, which she joined in the Fall of 2023. Emily joined the Fritz lab in 2024 where she researches metabolic and redox dysregulation in Alcohol-associated Liver Disease. She focuses on protein post-translational modifications on cysteine and lysine residues, and mechanisms of protein regulation through lysine deacetylation by sirtuins. Through investigation of the hepatoprotective role of sirtuin 1 activation, her aim is to further the understanding of early progression of Alcohol-associated Liver Disease and identify diagnostic and therapeutic targets.
Jon Woodward
Jon Woodward joined the Toxicology PhD program at the University of Colorado, Anschutz Medical Campus in the Fall of 2022 and joined the lab of Dr. Rebecca McCullough in 2023. Jon’s research focuses on characterizing novel mechanisms of Per- and Polyfluoroalkyl Substances (PFAS) that drive early stages of hepatic steatosis. Specifically, his thesis work investigates the interactions between prevalent next-generation PFAS compounds and Sirtuins, a group of proteins that are involved with a myriad of cellular processes, including lipid metabolism. He aims to enhance knowledge regarding how PFAS compounds interact and inhibit Sirtuins, helping to explain current gaps in our understanding of PFAS-driven lipid accumulation in hepatocytes. He hopes that this work may highlight novel targets leading to the development of interventional strategies to improve exposure outcomes in humans while also informing future regulatory policies for PFAS use and exposure in the United States.
Chanapa Mann
Chanapa Mann joined the Toxicology PhD program at the University of Colorado, Anschutz Medical Campus in the Fall of 2023 and joined the lab of Dr. Manisha Patel in 2024. Her current research focuses on the molecular mechanisms underlying heat-inducible seizure sensitivity in Dravet Syndrome (DS), a severe developmental and epileptic encephalopathy. Specifically, she aims to elucidate how hyperthermic challenge can exacerbate inherent bioenergetic deficits in DS which may predispose neurons to seizure initiation. Given that rising global temperatures have been increasingly associated with elevated hyperthermic seizure risk, genetically vulnerable populations, such as individuals with DS, will be disproportionately impacted. A better understanding of how metabolic pathways critical for neuronal function are altered in the context of hyperthermic seizures will be foundational to the development of novel therapeutic strategies that consider the multifacetedness of gene-environment interactions.
Sarah Asby
Colin Anderson – currently a Postdoctoral Research Fellow at the Buck Institute for Research on Aging
Dustin Brown – currently a Molecular Toxicologist at the Food and Drug Administration
Angela Cruz-Hernandez – currently a Senior Scientist in Product Safety at L’Oreal
Michaela Hvizdak
Kendra Prutton – currently a Science Communications and Education Manager at International Society for Stem Cell Research
Angela Reinert
Keegan Rogers – currently a Health Scientist at Stantec Chemrisk
Brandon Sonn – currently a Medical Science Liaison and Precision Medicine Researcher at Strata Oncology
Shannon Twardy- currently on an F31 in Dr. Rebecca McCullough's Laboratory at CU Anschutz
Rajesh Agarwal
Cancer/Natural Products
Alison Bauer
Environmental Lung Disease
Jared Brown
Immunotoxicology/Nano
Shaodong Dai
Metals/Autoimmunity
Andrew Fontenot
Pulmonary/Microbiome
Kris Fritz
Metabolic Syndrome/Ethanol
Li Li
Beryllium Disease
Lisa Maier
Environmental Lung Disease
Manisha Patel
Neurotoxicology
Vanessa Phelan
Microbiome/Lung
Nichole Reisdorph
Metabolomics/Asthma
James Roede
Pesticides/Neurotoxicology
Laura Saba
Bioinformatics/Statistics
David Schwartz
Environmental Lung Disease
Carl White
Lung Disease/Chemical Warfare
Ivana Yang
Epigenomics/Asthma
Jared Brown PhD
Professor
T32 Training Program in Molecular and Systems Toxicology Director, Colorado Center for Nanomedicine and Nanosafety Co-Director
Phone:303-724-8213
